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Abstract
Background: Description of the clinical pictures of patients colonized or infected by ESBL-producing
Enterobacteriaceae isolates and admitted to hospital are rather scarce in Europe. However, a better delineation of
the clinical patterns associated with the carriage of ESBL-producing isolates may allow healthcare providers to
identify more rapidly at risk patients. This matter is of particular concern because of the growing proportion of
ESBL-producing Enterobacteriaceae species isolates worldwide.
Methods: We undertook a descriptive analysis of 114 consecutive patients in whom ESBL-producing
Enterobacteriaceae isolates were collected from clinical specimens over a 20-month period. Clinical data were
obtained through retrospective analysis of medical record charts. Microbiological cultures were carried out by
standard laboratory methods.
Results: The proportion of ESBL-producing Enterobacteriaceae strains after exclusion of duplicate isolates was 4.5%
and the incidence rate was 4.3 cases/1000 patients admitted. Healthcare-associated acquisition was important
(n = 104) while community-acquisition was less frequently found (n = 10). Among the former group, two-thirds of
the patients were aged over 65 years and 24% of these were living in nursing homes. Sixty-eight (65%) of the
patients with healthcare-associated ESBL, were considered clinically infected. In this group, the number and severity
of co-morbidities was high, particularly including diabetes mellitus and chronic renal insufficiency. Other known risk
factors for ESBL colonization or infection such as prior antibiotic exposure, urinary catheter or previous
hospitalisation were also often found. The four main diagnostic categories were: urinary tract infections, lower
respiratory tract infections, septicaemia and intra-abdominal infections. For hospitalized patients, the median
hospital length of stay was 23 days and the average mortality rate during hospitalization was 13% (Confidence
Interval 95%: 7-19). Escherichia coli, by far, accounted as the most common ESBL-producing Enterobacteriaceae
species (77/114; [68%]) while CTX-M-1 group was by far the most prevalent ESBL enzyme (n = 56).
Conclusion: In this retrospective study, the clinical profiles of patients carrying healthcare-associated ESBL-producing
Enterobacteriacae is characterized by a high prevalence rate of several major co-morbidities and potential known risk
factors. Both, the length of hospital stay and overall hospital mortality rates were particularly high. A prospective
case-control matched study should be designed and performed in order to control for possible inclusion bias.
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Antimicrobial resistance is a major public health con-
cern in human medicine both in the community and in
medical institutions [1]. Aged patients, especially frail
elderly, constitute a subgroup of persons which seems
more affected than other population groups. For
instance, the carriage of methicillin-resistant Staphylo-
coccus aureus (MRSA) in acute care hospitals has been
well documented in Belgium since the early nineties [2].
Over the last years, large reservoirs of MRSA carriers
have been identified among elderly subjects living in
nursing homes [3]. A recent cross-sectional survey car-
ried-out in 2005 among 60 Belgian nursing homes (NH)
showed an average prevalence rate of MRSA carriage as
high as 20% of the residents (with ranges between 2 and
42%) [4]. By contrast, epidemiologic surveys of multi-
drug resistant gram-negative microorganisms (MDR)
have been very scarce and the current prevalence of
such organisms currently remains only partially known
in most European structures of care, especially in long-
term care facilities [5-7]. Initial reports of ESBL-produ-
cers in the eighties and early nineties essentially focused
on the descriptions of nosocomial outbreaks, mainly in
intensive care unit settings, caused by Klebsiella and
Enterobacter spp. which produced various TEM- or
SHV- ESBL subtypes [8]. More recently, novel ESBLs
coding genes (e.g. of the CTX-M family) derived from
plasmid mobilization of environmental or soil organisms
have emerged worldwide in several enterobacteria
species particularly in E. coli [9]. The CTX-M ESBLs are
most often encountered in association with community-
acquired infections rather than with hospital outbreaks
[8]. In a nationwide surveillance program, the propor-
tion of ESBL-producing E. coli isolated from clinical
specimens referred to hospital-based laboratories was
found to rise from 3.6% in 2005 to 4.8% in 2008 [10,11].
Reports depicting the clinical pictures and profiles of
patients colonized or infected by ESBL-producing Enter-
obacteriaceae isolates and admitted to hospital have
mainly been published from the United States, Canada
or Israel but are rather limited in Europe [8,9,12]. In
order to gain a better insight of the epidemiology and
the risk factors associated with ESBLs, we undertook a
descriptive analysis of the clinical charts of patients in
whom ESBL-producing microorganisms had been iso-
lated from clinical samples.
Methods
Study Population
The study took place at Mont-Godinne hospital, Catho-
lic University of Louvain - UCL, a 370-bed tertiary-care
teaching hospital located in a rural area in the southern
part of Belgium. This hospital mainly provides acute
care diagnostic and treatment services including
cardio-vascular surgery, chronic respiratory diseases and
onco-haematology and it compr i s e s2 7b e d so fg e r i a t r i c
medicine as well as 20 beds of rehabilitation. Ambulatory
care, including one-day clinic and geriatric day hospital
are also provided.
Study Design
In this retrospective descriptive survey carried-out over
a 20-month period between January 2008 and August
2009, 114 patients were found to be colonized or
infected with one ESBL-producing Enterobacteriaceae
isolates. This study took part in the setting of a compre-
hensive program aimed to improve hygiene and infec-
tion control locally. Despite the limitation to its
retrospective character, this study was undertaken
because it was estimated that it could provide easily
interesting clinical and microbiological informations in
patients colonized or infected with an ESBL-producing
microorganism before planning a prospective study.
Since all isolates were considered sporadic and because
no nosocomial outbreaks were occurring at the time of
the study, no systematic screening for ESBL carriage
was performed upon admission to hospital.
Data Collection
All patients’ demographic and microbiological data were
recorded in an electronic database. Clinical data were
collected by retrospective analyses of computerized
medical charts.
Clinical data included several demographics variables
such as age, gender and geographic area of residency.
Significant co-morbidities (diabetes mellitus, chronic
renal insufficiency, congestive heart failure, chronic
respiratory disease, liver disease, haematological malig-
nancies) were collected using the Cumulative Illness
Rating Scale for Geriatrics (CIRS-G) [13]. This scale is
used for a comprehensive review of medical problems
by organ systems, based on a 0 through 4 rating, yield-
ing a cumulative score. Every single disease has to be
classified in one of the 14 appropriate systems and rated
according to its severity: 0: past problem without clinical
relevance, 1: past significant problem or current mild
problem, 2: moderate disability or first line therapy
needed, 3: severe problem with constant disability or
hard to control chronic problems, 4 extremely severe
problem or immediate treatment required or severe
functional impairment. For this scale, we choose to
report results using the mean global score (which in
theory can vary from 0 to 56) and the mean number of
different categories of affected systems (from 0 to 14
systems) [14]. For hospitalised patients, the mean Nor-
ton index was recorded from the medical charts
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of the first identification of the ESBL [15,16]. The Nor-
ton scale is a risk assessment scale used for prediction
of pressure sore development among elderly patients.
The scale included five variables rated from 0 to 4 (gen-
eral medical condition, mental state, level of activity,
level of mobility and incontinence). With a maximum
score of 20, a cut-off below 14 has been used to predict
patients at risk of pressure sores.
We classified patients in two different groups accord-
ing to the presence of microbiological colonization by
an ESBL-producing organism only or to the occurrence
of presumed or proven infection. Colonization was
defined by the absence of clinical signs of active
infection and by the absence of antibiotic administration
during the hospital stay after the detection of an ESBL-
producing isolate. Infections were categorized by anato-
mical sites as well as by their most probable origin of
acquisition (community- versus healthcare-setting).
Healthcare-associated acquisition of an ESBL-producing
Enterobacteriaceae was defined as follow: residency in a
nursing home before admission, hospitalization within
the previous 12 months or multiple contacts with the
hospital within the previous year (≥ 3c o n t a c t sw i t h i n
the previous 12 months including patients in ambulatory
care clinic or attendance to the emergency room). Com-
munity-acquisition referred to organisms that were iso-
lated from clinical specimens of non-hospitalized
patients and in the absence of any of the criteria used
for healthcare-acquisition.
Putative known risk factors for carriage of multi-drug
resistant pathogens were also recorded: prior exposure
to antimicrobial drugs (defined as a categorical variable,
e.g. exposure or no exposure), hospitalization within the
previous 12 months, duration of stay exceeding 8 days
(the average duration of hospital stay at our hospital),
previous hospitalization in the intensive care unit (ICU),
previously known MRSA carriage, pressure sores and/or
wounds, and presence of chronic catheters (urinary
catheter, percutaneous gastrostomy and tracheotomy)
[9].
Microbiological data included the anatomic sites of
isolation, species identification, the type of ESBL as well
as the antimicrobial in vitro susceptibility and resistance
patterns.
Patient’so u t c o m e swere defined (for inpatients only)
as the mortality rate during hospitalization and the med-
ian length of hospital stay (LOS).
Microbiological analyses
Bacterial isolates were identified by conventional micro-
biological methods and tested for in vitro susceptibility
using the disk diffusion method according to Clinical
Laboratory Standards Institute (CLSI ) guidelines [17]
and by automated Vitek 2 system (AST-046 susceptibil-
ity cards) (bioMérieux, Marcy l’Étoile, France). The pre-
sence of ESBL was detected by a two-step approach as
per recommendations of the CLSI [17]: i.e. screening of
resistance to 3
rd generation cephalosporins by MIC and/
or disk diffusion testing and by phenotypic confirmatory
tests for the presence of ESBLs (disc diffusion and/or
MIC susceptibility testing of 3
rd generation cephalospor-
ins in the presence of clavulanic acid). For AmpC-indu-
cible species, a double combination disc test with
ceftazidime and cefotaxime alone or in the presence of
clavulanic acid was performed in the presence of phe-
nylboronic acid (400 μg) spotted on discs and by cefe-
pime, alone and with clavulanic acid, as an additional
test [18]. A difference in diameters of ≥ 5m mi nt h e
presence of clavulanic acid was deemed as a positive
ESBL result.
Detection and characterization of ESBLs was carried
out by a commercial multiplex ligation PCR microarray
(Check-Points
®, Wageningen, The Nederlands) targeting
the most common ESBL coding genes (i.e. blaTEM,
blaSHV and blaCTX-M) [19].
Statistical analysis
Numerical data are expressed as mean ± standard devia-
tion and inter-quartile range. We used the Wilcoxon
Rank-Sum test for numerical data. Categorical data were
compared by chi-square test or by Fisher’s exact test if
appropriate. All tests are two-tailed and were performed
by SPSS 15.0 software (SPCC Inc., Chicago, Illinois).
Confidentiality and ethical aspects
This study protocol was approved by the central ethics
committee of the Cliniques Universitaires UCL de
Mont-Godinne (Intern identification number:78/2009)
and it respects principles of the Helsinki Statement and
the Belgian law for Good Clinical Practices from May
7th, 2004 relative to experiment on humans.
Results
Overall, 114 patients were included in the study. During
the 20-month period of the study, the total number of
admission was 26,727 and the number of hospitalisa-
tion-days was 198,476. The number of routine microbio-
logical samples analysed during this period of time was
53,545 (urinary analyses: 14,342, blood cultures: 17,339,
respiratory tract samples: 8,782 and wounds or swabs:
13,082). The prevalence of ESBL-producing Enterobac-
teriacae isolates recovered from clinical samples
(excluding duplicate isolates from the same patient) was
4.5% [114/2525]. The incidence rate of colonization/
infection caused by ESBL-positive Enterobacteriaceae
isolates was 4.3 cases/1000 admitted patients and 0.57
cases/1000 hospitalization days.
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the probable healthcare-associated or community origin
of acquisition of ESBL-producing Enterobacteriaceae.
Because of the study design and of the hospital-case mix
of the population (85-90% of clinical specimens sub-
mitted to the laboratory originated from hospitalized
patients), the healthcare-associated ESBL+ group was
the most important (n = 104 [91%]) while the commu-
nity acquired ESBL+ group was smaller (n = 10 [9%]).
Compared with the group of patients with healthcare-
associated ESBLs, patients with community-acquired
ESBLs originated mostly from the ambulatory clinic
(n = 7), were significantly younger (52 ± 20 years;
P < 0.001) and were more frequently asymptomatic car-
riers (Escherichia coli (n = 8) harbouring CTX-M1
group ESBL) (P: 0.005).
The most salient clinical characteristics of the 104
patients with healthcare-associated colonization or infec-
tion are presented in Table 1. Their mean age was 70 ±
13 years (inter-quartile range: 62-79) with a sex ratio
men/women of 1.2. Two-thirds of them were over 65
years of age. Twenty-four percent of the subjects in this
subgroup were living in a nursing home (NH). At the
time of microbiological sampling, 89 patients (86%)
were hospitalized and 15 subjects (14%) were ambula-
tory care patients.
Hospitalized patients colonized or infected with an
ESBL producer were admitted in all types of wards
including surgery (n = 43), internal medicine (n = 17),
intensive care unit (n = 11), oncology/haematology (n =
10), and geriatric wards (n = 8). A high number of
co-morbid conditions were present in these patients
(diabetes mellitus (23%), chronic renal insufficiency
(23%), congestive heart failure (13%), chronic respiratory
disease (16%), and haematological malignancies (8%)).
The mean CIRS-G global score was 10.5 ± 3.9 (mean
number of different categories: 5.2 ± 2.0) and the mean
Norton Index was 14.8 ± 3.6. Intravascular, bladder
catheter or gastrostomy tubes were present in half of
the patients. Other risk factors commonly present for
the acquisition of a MDR-bacteria were also found; two-
thirds of the hospitalized patients had been previously
exposed to antibiotics (with a mean of two different
antibiotic regimens) prior to the isolation of an ESBL-
producing organism, over 60% of them had been hospi-
talized or had had multiple medical contacts with the
hospital within the last 12 months, and 29% of the
patients had been hospitalized in the ICU during hospi-
talization before detection of an ESBL.
The list of antimicrobial agents prescribed in the time
elapsed between hospital admission and the first known
isolation of an ESBL-producing microorganism is
reported in Table 2. Fifty-three percent (n = 52) of the
patients had received cephalosporins, 32% (n = 30) had
received a broad-spectrum penicillin (amoxicillin-clavu-
lanate, piperacillin-tazobactam) and 13% (n = 12) had
had a previous course of therapy with a fluoroquinolone
agent.
Sixty-eight (65%) of the hospitalized patients were
considered as infected while 36 patients were asympto-
matic carriers of an ESBL-producing Enterobacteriaceae
isolate (35%). The four major documented infections
were: urinary tract infection (UTI) (n = 38, [56%]),
lower respiratory tract infection (RTI) (n = 18, [27%]),
septicaemia (n = 6, [9%]) and intra-abdominal infections
(n = 3, [4%]).
The median hospital length of stay (LOS) was 23 days
(inter-quartile range: 13-39 days) and the overall mortal-
ity rate during hospitalization was 13% (Confidence
Interval 95% [95% CI]: 7-19). During the study period,
the average LOS in the institution was of 7.4 days while
the number of death was 602 (2.3 cases/100 admitted
patients).
A fatal outcome was documented only in patients with
ESBL-producing bacteria of healthcare-associated onset
(12 deceased patients out of 104 vs. 0 out of 10 in those
with community acquired ESBL; P = 0.01). Compared to
patients who were still alive at the end of their hospital
stay, deceased patients had a significantly higher mean
LOS (42 ± 30 days; P: 0.05). Six out of the 12 patients
who died were hospitalized in the ICU at the time of
death. Of the 12 patients with a fatal outcome, 10
patients were infected (5 lower respiratory tract infec-
tion, 3 bloodstream infection and 2 urinary tract infec-
tion) while 2 only were ESBL carriers. However,
mortality could be directly attributed to the infection in
only 5 of the 10 cases.
The median time elapsed between hospital admission
and the subsequent isolation of an ESBL-producing
Enterobacteriaceae isolate was 7 days (inter-quartile
range: 1-18 days). Microbiological data for healthcare-
associated detection of ESBL-producing Enterobacter-
iaceae a r es h o w ni nT a b l e3 .Escherichia coli
accounted as the most frequent species (n = 69,
[66%]), followed by Enterobacter spp. (n = 21 [22%]:
E. aerogenes (n = 14) and E. cloacae (n = 7)) and Kleb-
siella spp. (n = 12 [12%]: K. pneumoniae (n = 11) and
K. oxytoca (n = 1)). ESBL enzymes of the CTX-M-1
group were the most frequently found (n = 51, [49%])
followed by TEM-types (n = 28, [27%]), SHV-types
(n = 28, [27%]), CTX-M-9 (n = 8, [8%]) and CTX-M-2
groups (n = 6, [6%]). Enzymes of the CTX-M-1 group
were essentially detected among E. coli while the other
types of ESBLs were more frequent in other bacterial
species. As anticipated, E. coli was more frequently
found in association with urinary tract infections (32/
38, [84%] in UTIs versus 14/30, [47%] in other types of
infections; P < 0.001).
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This study reports the clinical patterns in a cohort of
subjects carrying ESBL-producing Enterobacteriaceae
isolates over a 20-month period. We found that a two-
thirds of the patients carrying ESBLs were elderly adults
aged over 65 years and who presented a large variety of
co-morbidities (on the average, 5 ± 2 different organs
affected per patient), as illustrated by the high mean
score of the CIRS-G index. Interestingly, the majority of
these patients (whether being asymptomatic carriers or
whether presenting an ESBL infection) had had several
hospitalizations or multiple contacts with the hospital
Table 1 Clinical data of patients with a healthcare-associated colonization or infection by an Extended-Spectrum Beta-
Lactamase (ESBL) producing microorganism
Characteristics of patients Healthcare-associated group N = 104 (91%)
Demographic characteristics:
Male sex 56 (54)
Age: median; years (inter-quartile range) 71 (62-79)
Patients over 65 years 67 (64)
Nursing home residents, n (% of patients over 65 years) 16 (24)
Proportion of ambulatory or hospitalized patients:
Outpatients 15 (14)
Inpatients 89 (86)
Co-morbidities:
CIRS*: mean global score ± SD (inter-quartile range) 10.5 ± 3.9 (8-13)
CIRS: mean nr of different categories ± SD (inter-quartile range) 5.2 ± 2.0 (4-7)
Mean Norton Index ± SD;/20 points (inter-quartile range) 14.8 ± 3.6 (12-18)
Diabetes Mellitus 24 (23)
Chronic renal insufficiency 24 (23)
Heart failure 13 (12.5)
Severe chronic respiratory disease 17 (16)
Cirrhoses 3 (3)
Haematological malignancies 8 (8)
Pressure ulcers 16 (15)
Urinary catheters 38 (37)
Wounds 34 (33)
PEG** or tracheotomy 7 (7)
Medications:
Proton pump inhibitors 34 (33)
Histamine2 receptor antagonist 25 (24)
Number of patients previously exposed to antibiotics: 60 (58)
Mean antibiotic use ± SD (inter-quartile range) 2 ± 1.5 (1-3)
Clinical infection due to an ESBL microorganism: 68 (65)
Urinary tract infection 38 (55.9)
Respiratory tract infection 18 (26.5)
Bloodstream infection 6 (8.8)
Others 6 (8.8)
Simple ESBL carriers (colonization): 36 (35)
Previous known MRSA carriage: 9 (9)
Contact with health care system:
Previous hospitalization within 1 year 68 (65)
Multiple contacts within 1 year 71 (68)
Admission to ICU
§ during current hospitalization 30 (29)
Median overall LOS
§§, days (inter-quartile range): 23 (13-39)
Proportion with a long LOS (≥ 8 days) 77 (87)
Number of death: 12 (12)
Data are provided in absolute number and percentage between brackets. * CIRS: Cumulative Illness Rating Scale for Geriatrics; **PEG: Percutaneous Endoscopic
Gastrostomy; § ICU: Intensive Care Unit; §§ LOS: Length of hospital stay;
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patients who had received one or more courses of anti-
microbial therapy before the isolation of an ESBL-posi-
tive strain was high (58%, n = 60). It is most probable
that the frequent exposure to previous antimicrobial
treatment played a major role in the selection of ESBL-
producing organisms as previously demonstrated in sev-
eral case-control studies [6,20-22]. Further, antibiotic
exposure is also known as a risk factor for the develop-
ment of community-acquired bacteraemia caused by
ESBL-producing E. coli [7], but due to the small number
of patients with true community-acquired ESBL infec-
tion in our cohort we were not able to confirm this in
the present study. In their comprehensive review of the
literature, Pitout et al. highlighted the previous usage of
antimicrobial agents (in particular cephalosporins), the
severity of illnesses, a longer duration of hospital stay
especially in the intensive care unit and the presence of
urinary or arterial catheterisation as independent risk
factors for the development of health-care associated
ESBL infections [8].
One recent study in France, also highlighted the
importance of inter-hospital transfer, especially after
hospitalization in a foreign country, the previous car-
riage of an ESBL-producing Enterobacteriaceae or the
presence of a chronic illness as risk factors for the
acquisition of ESBLs [23]. Interestingly, these investiga-
tors also found that 4% of admitted patients without any
potential risk factors were ESBL+ at entry.
The retrospective design of our study did not allow to
establish the risk of co-colonization by ESBL-producing
gram-negative bacilli and by other drug resistant
bacterial pathogens such as methicillin-resistant Staphy-
lococcus aureus (MRSA) or vancomycin-resistant Entero-
cocci (VRE). However it was interesting to note that 9%
(n = 9) of the patients colonized by an ESBL-producing
organism were also known as previous MRSA carriers.
The risk of co-colonisation probably reflects the occur-
rence of common risk factors for colonization or infec-
tion by different types of nosocomial pathogens [24].
The median LOS of 23 days and the 13% mortality
rate observed here appear as much higher figures than
the expected average rates observed at our institution
(7.4 days and 2.3 death/100 admitted patients respec-
tively). Lautenbach et al. also reported a longer LOS
(OR: 1.74) and they documented higher hospital costs
(OR: 2.9) associated with infections caused by an ESBL-
producing E. coli or K. pneumoniae organism in com-
parison to a matched-control group of patients infected
with organisms belonging to these same species but that
were not producing an ESBL [25]. Furthermore, a posi-
tive association has also been reported between the LOS
and the risk of colonization by an ESBL-producing
microorganism. For instance, Friedmann et al. found in
a non-outbreak setting that one-third of patients in gen-
eral medicine wards (mean age of 76 ± 13 years), were
colonized by ESBL-producing Enterobacteriaceae after a
course of hospitalization of 2 weeks [12].
Several case-control studies have suggested that infec-
tions caused by ESBL-producing Enterobacteriaceae spe-
cies were associated with a higher mortality rate as
compared to infections caused by the same organisms
but lacking an ESBL [26-28]. A recent meta-analysis
concluded that bacteraemia caused by ESBL-producing
Enterobacteriaceae was associated with an increased
mortality rate (pooled Relative Risk [RR]: 1.85, 95%CI:
1.39-2.47, P < 0.001) and that delayed effective therapy
did further increase the mortality (pooled RR: 5.56, 95%
CI: 2.94-10.51, P < 0.001) [29]. Nevertheless, the real
attributable impact of ESBL infection on mortality
remains controversial and a critical review of the litera-
ture does not provide clear answers to this matter [28].
The lack of well-powered studies, the importance and
clinical severity of the underlying illnesses, the appropri-
ate or inappropriate choice of empirical therapy, as well
as variable performance of microbiology laboratories to
detect and report ESBL microorganisms, might all be
limiting factors or confounding variables for a correct
interpretation of the data. Well designed prospective
studies are thus clearly warranted to address this impor-
tant issue [28].
As anticipated, we found that E. coli by far accounted as
the most frequent ESBL-producing enterobacteria species.
A recent study carried out in 2004 and involving 16
laboratories in London and in the South-Eastern part of
England showed that among 1127 cephalosporin-resistant
Table 2 Antibiotic treatment courses administered prior
to the isolation of an Extended-Spectrum Beta-Lactamase
(ESBL) microorganism among hospitalized patients
Antibiotic treatment ATC class N (%)
Penicillins: J01CE01 3 (3)
Aminopenicillins: J01CA04/J01CA01 4 (4)
Carboxypenicillins:
Temocillin: J01CA17 3 (3)
Flucloxacillins: J01CF05 5 (5)
Amoxicillin-clavulanate J01CR02 14 (15)
Piperacillin-tazobactam: J01CR05 16 (17)
Cephalosporins:
Cefazolin: J01DB04 22 (24)
Cefuroxime: J01DC02 11 (13)
Ceftriaxone: J01DD04 5 (5)
Ceftazidime: J01DD02 5 (5)
Cefepime: J01DE01 5 (5)
Meropenem: J01DH02 3 (3)
Fluoroquinolones: J01MA14/J01MA02 12 (13)
Aminoglycosides: J01GB06/J01GB03 8 (9)
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settings, E. coli also accounted as the largest group (51%)
and, in particular, CTX-M producing strains [30]. The
high prevalence of CTX-M-1 group ESBLs (mainly com-
prising the CTX-M-15 type) is an emerging and well
described problem worldwide [31-37]. While most pub-
lished reports until the 1990’s found a predominance of
SHV- or TEM-type ESBLs associated with nosocomial
outbreaks, the epidemiology dramatically changed over
the last ten years. The extensive dissemination of E. coli in
the community [37] and its subsequent spread in hospitals
illustrates the importance of movement of patients
between the community and the healthcare system, in par-
ticular between nursing homes and acute hospitals. Data
from our study further highlight this emerging pattern. In
France, a progressive increase in the occurrence of CTX-
M enzymes linked to E. coli has also been reported
[31,37]. In Belgium, a three-fold increase of the prevalence
of multi-resistant CTX-M producing E. coli was detected
between 2000 and 2004 [38] and over 50% of the ESBL-
producing Enterobacteriaceae isolates identified in human
clinical isolates in Belgium in 2008 belong to the CTX-M
[39]. CTX-M-15 (75% of all CTX-M ESBLs) and CTX-M-
2 to a lesser extent currently account as the most predo-
minant ESBLs of the CTX-M type in Belgium and this
likely reflects both clonal dissemination as well as plasmid
epidemics across different bacterial species (Salmonella
enterica and E. coli)i na n i m a l sa n di nh u m a n s[ 4 0 ] .
There have been only few studies which did recently
address the epidemiology of ESBL-producing Enterobac-
teriaceae in Belgium, and the present report gives some
insights on the clinical patterns of healthcare associated
colonization or infection caused by ESBL-producing
Enterobacteriaceae.
We do however recognize the limitations of this retro-
spective study which was only based on the collection of
Table 3 Microbiological data for patients with a healthcare-associated colonization or infection by an Extended-
Spectrum Beta-Lactamase (ESBL)-producing microorganism
Characteristics of patients Healthcare-associated group N = 104 (91%)
Proportion of clinical samples:
Urinary tract samples 59 (57)
Respiratory tract samples 22 (21)
Wounds swabs 11 (11)
Blood cultures 10 (10)
Others (stool, biopsy) 2 (2)
Isolated microorganisms and types of ESBLs:
Escherichia coli 69 (66)
-CTX-M-1 group 45 (65)
-CTX-M-2 group 6 (9)
-CTX-M-9 group 5 (7)
-TEM 10 (14)
-SHV 3 (4)
Enterobacter spp. 21 (22)
-CTX-M-9 group 2 (10)
-CTX-M-1 group 1 (5)
-TEM+SHV 14 (67)
-TEM 2 (10)
+SHV 2 (10)
Klebsiella spp. 12 (12)
-CTX-M-1 group 2 (17)
-CTX-M-1+SHV 1 (8)
-CTX-M-9 group 1 (8)
-TEM 2 (17)
+SHV 6 (50)
Others 2 (2)
Time elapsed from admission to positive culture:
< 72 hours 30 (34)
3-7 days 12 (13)
8-14 days 19 (21)
> 14 days 28 (31)
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carried out to detect asymptomatic carriage upon hospi-
tal admission. Comparing and translating data obtained
from studies carried out in epidemic or endemic settings
with a systematic screening approach may therefore be
difficult.
Further, we acknowledge the fact that the selection of
patients from clinical samples submitted to a hospital-
based laboratory may have introduced some bias.
Indeed, almost 90% of the clinical specimens submitted
for microbiological analysis to our bacteriology labora-
tory originate from hospitalized patients and/or from
subjects with frequent contacts with the healthcare
system. This may be explained by the fact that our hospi-
tal is geographically located in a rural area and that over
90% of the microbiological specimens received in our
laboratory originates either from hospitalized patients or
from patients regularly visiting the polyclinics; thus the
group of patients with true community acquired infec-
tions clearly constitutes a minor proportion in our
setting.
The lack of a control group constitutes a limiting fac-
tor excluding possible comparisons of odds ratios for
clinical risk factors.
Despite all the limitations we think these data may be
interesting for the following reasons: Apart from of one
recent microbiological report of ESBLs isolated from
humans in Belgium [40], our study constitutes one of
the first attempt of a global clinical description of a
large cohort of patients colonized or infected by ESBL-
producing gram-negative bacilli at one university hospi-
tal. Since the majority of the patients were aged over 65
years, the patient’s characteristics were also defined with
geriatric tools such as the Cumulative Illness Rating
Scale for Geriatrics and the Norton Index. The reliance
on these objective scales and indexes may be useful to
develop algorithms and screening strategies aiming to
select at risk groups in this population upon hospital
admission. Urinary tract and respiratory tract infections
were the two major diagnostic categories and these
indeed constitute the most frequent types infections
among elderly patients admitted in general internal
medicine or geriatric wards. While most clinicians do
currently recognize the importance of MRSA screening
upon hospital admission, few teams would consider
assessing the potential risk factors for ESBL carriage
upon hospital admission. Nevertheless, asymptomatic
intestinal carriage of ESBLs could represent as for
MRSA an important risk factor for the development of
subsequent infections. One study carried out in a large
cohort of elderly patients screened upon hospital admis-
sion in Israel showed an increase rate of subsequent
bacteraemia for ESBL faecal carriers (15% versus 0.5%;
odds ratio: 38.9; P < 0.001) [5]. A more comprehensive
approach may also lead to improvement in the choice of
empiric antibiotic treatment, infection control proce-
dures and patient outcomes.
We strongly believe that multidisciplinary work invol-
ving geriatricians, infectious diseases specialists, infec-
tion control units and the microbiological laboratory
could improve clinical practice and help reducing anti-
biotic pressure [41].
Conclusion
Prospective studies with systematic screening of asymp-
tomatic ESBL carriage in subjects residing in nursing
homes and in elderly patients upon admission to hospi-
tals in geriatric wards are necessary to improve our
knowledge on the dynamic of acquisition and transmis-
sion of ESBLs between different human sectors.
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